Department of Ophthalmology, Capital and Coast DHB, Wellington, New Zealand.
Royal Victoria Eye and Ear Hospital, Melbourne, Australia.
Ophthalmol Glaucoma. 2021 Sep-Oct;4(5):482-489. doi: 10.1016/j.ogla.2020.12.013. Epub 2021 Jan 9.
To characterize intraocular pressure (IOP) reduction, effect duration, and side effect profile of repeat selective laser trabeculoplasty (SLT) used as primary stand-alone treatment for open-angle glaucoma (OAG). The secondary aim was to investigate covariates associated with treatment response to SLT.
Retrospective chart review.
A total of 52 patients with treatment-naïve OAG who received 3 installments of 360 SLT as stand-alone glaucoma therapy. When both eyes met the inclusion criteria, only right eye data were used for analysis.
The study was conducted in a single specialist practice. First, second, and third SLT (SLT1, SLT2, SLT3, respectively) treatments were compared for IOP reduction and effect duration. Eyes were classified as "treatment responders" if they had ≥20% IOP reduction 4 to 8 weeks post-SLT compared with baseline. Effect duration was the interval between SLT and the time point at which the surgeon decided inadequate IOP control necessitated repeat SLT. Individuals were excluded if they underwent intraocular surgery during the study period or received treatment with adjunctive ocular hypotensive medications.
Reduction in IOP post-SLT and effect duration between treatments.
Mean age at SLT1 was 58 years; 50% were male, and 92% were phakic. The SLT1 and SLT3 both resulted in mean 27% IOP reduction at 4 to 8 weeks, whereas SLT2 led to 26% IOP reduction. Response rate (≥20% IOP reduction at 4-8 weeks) was 79% for SLT1, 73% for SLT2, and 81% for SLT3, but the difference was not statistically significant. Response to repeat SLT was not significantly associated with previous SLT outcome. Effect duration was 22.2 months, 33.8 months, and 28.9 months after SLT1, SLT2, and SLT3, respectively. Effect duration was significantly longer after SLT2 (P = 0.0006) and SLT3 (P = 0.0444) compared with SLT1. There was no significant association between SLT response and gender, lens status, or OAG subtype.
For primary stand-alone treatment in OAG, initial and repeat SLTs produced comparable percentage IOP reduction, but repeat SLTs had longer effect duration. Intraocular pressure response to SLT was not predictive of the IOP response to subsequent, repeat SLT treatment.
描述选择性激光小梁成形术(SLT)作为原发性独立治疗开角型青光眼(OAG)的眼压(IOP)降低、作用持续时间和副作用特征。次要目的是研究与 SLT 治疗反应相关的协变量。
回顾性图表审查。
52 名患有治疗初发 OAG 的患者,他们接受了 3 次 360°SLT 作为独立的青光眼治疗。当双眼符合纳入标准时,仅使用右眼数据进行分析。
该研究在一家专科诊所进行。比较了首次、第二次和第三次 SLT(SLT1、SLT2、SLT3)治疗的 IOP 降低和作用持续时间。如果与基线相比,SLT 后 4 至 8 周的 IOP 降低≥20%,则将眼睛分类为“治疗反应者”。作用持续时间是指从 SLT 到医生决定需要重复 SLT 以控制眼压不足的时间点之间的间隔。如果在研究期间接受了眼内手术或接受了辅助降眼压药物治疗,则将个体排除在外。
SLT 后 IOP 降低和治疗之间的作用持续时间。
SLT1 的平均年龄为 58 岁;50%为男性,92%为有晶状体眼。SLT1 和 SLT3 在 4 至 8 周时均导致平均 27%的 IOP 降低,而 SLT2 导致 26%的 IOP 降低。SLT1 的反应率(4-8 周时 IOP 降低≥20%)为 79%,SLT2 为 73%,SLT3 为 81%,但差异无统计学意义。重复 SLT 的反应与先前 SLT 结果无显著相关性。作用持续时间分别为 SLT1 后 22.2 个月、SLT2 后 33.8 个月和 SLT3 后 28.9 个月。与 SLT1 相比,SLT2(P=0.0006)和 SLT3(P=0.0444)的作用持续时间明显更长。SLT 反应与性别、晶状体状态或 OAG 亚型之间无显著关联。
对于原发性独立治疗 OAG,初次和重复 SLT 产生的 IOP 降低百分比相当,但重复 SLT 的作用持续时间更长。SLT 对眼压的反应不能预测对后续重复 SLT 治疗的眼压反应。